The POLISH study also found that for advanced NSCLC patients with HER2 mutations, chemotherapy + immunotherapy did not improve median PFS compared with chemotherapy + anti-angiogenic therapy or chemotherapy alone (both p > 0.05) [42]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.